Europäische Union - Kroatisch - EMA (European Medicines Agency)

intervet international bv - sojevi virusa influence konja: a / equine-2 / south africa / 4/03, a / equine-2 / newmarket / 2/93, tetanus toksoid - virus vozilima do konja gripe + клостридии - konji - aktivna imunizacija konja od šest mjeseci protiv influence konja zbog smanjenja kliničkih znakova i izlučivanja virusa nakon infekcije, te aktivne imunizacije protiv tetanusa radi sprječavanja smrtnosti.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

zoetis belgium sa - inaktivirani virus zapadnoga nila, soj vm-2 - imunološke za kopitare - konji - za aktivnu imunizaciju konja od šest mjeseci ili stariji protiv bolesti zapadnog nila virusom smanjenjem broja konjskih virusa.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

intervet international bv - interrogans серовара лептоспир серогруппы Кашницкого portland-vjeri (soj sa-12-000) i l. interrogans серовара copenhageni серогруппы icterohaemorrhagiae (soj sc-02-001), l. interrogans серогруппы Аустралис серовара bratislava (soj ac-05-073), l. kirschneri серогруппы grippotyphosa серовара dadas (soj gr-01-005) - immunologicals - psi - za aktivnu cijepljenja pasa protiv:interrogans серовара лептоспир серогруппы Кашницкого Тянитолкая za smanjenje infekcije i izlučivanje;l. interrogans серогруппы icterohaemorrhagiae copenhageni серовара za smanjenje infekcije i izlučivanje;l. interrogans серогруппы Аустралис серовара bratislava za smanjenje infekcije;l. kirschneri serogroup grippotyphosa serovar bananal / lianguang za smanjenje infekcije i izlučivanje urina.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

intervet international bv - Клостридии filtera tipa c / escherichia coli f4ab / f4ac e. coli / escherichia coli Ф5 / Ф6 e. coli / escherichia coli lt - immunologicals - svinje - za pasivne imunizacije potomstva kroz aktivne imunizacije krmača i подсвинков za smanjenje smrtnosti i kliničkih znakova tijekom prvih dana života, uzrokovano sojevi e. coli koji se izražavaju адгезинов f4ab (k88ab), f4ac (k88ac), Ф5 (u k99) ili f6 (987p) i uzrokovan clostridium filtera tipa c.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

intervet international bv - f4ab (k88ab) fimbrial адгезиного, f4ac (k88ac) fimbrial адгезиного, Ф5 (u k99) fimbrial адгезиного, Ф6 (987p) fimbrial адгезиного, lt анатоксина - immunologicals - svinje (nazimice i krmače) - za pasivnu imunizaciju prasadi aktivnom imunizacijom krmača / mliječi za smanjenje smrtnosti i kliničkih znakova kao što je proljev zbog neonatalne enterotoksikoze tijekom prvih dana života, uzrokovane tim e. coli koji eksprimiraju fimbrijske adhezije f4ab (k88ab), f4ac (k88ac), f5 (k99) ili f6 (987p).

Europäische Union - Kroatisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - virus mačje leukemije rekombinantnog kanarinaca (vcp97) - imunomodulatori za mačke, - mačke - aktivna imunizacija mačaka starijih od 8 tjedana protiv mačje leukemije radi sprečavanja perzistirajuće viremije i kliničkih znakova povezane bolesti. otkrivanje imuniteta pokazalo se 2 tjedna nakon primarnog cijepljenja. trajanje imuniteta je jedna godina nakon posljednjeg cijepljenja.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - imunomodulatori za mačke, - mačke - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Kroatisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.